Protocol Ledger

NCT07317934 · Phase III · RECRUITING

Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)

Interventional Phase III clinical trial protocol NCT07317934 sponsored by Innostellar Biotherapeutics Co in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-01-14 Enrollment: 388 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07317934
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)388 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07317934
Protocol FieldVerified Registry Value
NCT IdentifierNCT07317934
Consolidated Lead SponsorInnostellar Biotherapeutics Co
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment388 participants (ESTIMATED)
Registered Start Date2026-01-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07317934
Hospital Research SiteLocationSite Profile
Beijing HospitalBeijing, ChinaOpen Hospital Dossier ->
Peking Union Medical College HospitalBeijing, ChinaOpen Hospital Dossier ->
The Second Affiliated Hospital of Chongqing Medical UniversityChongqing, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI